Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 4/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.35 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29515400 | 1.00 | LMNA (0.39) | LMNADHFRHSP90AA1ADORA2AADORA1 | |
| SCHEMBL24330396 | 0.86 | HSP90AA1 (0.42) | DHFRHSP90AA1ADORA2AADORA1KMT2A | |
| SCHEMBL29515320 | 0.86 | HSP90AA1 (0.42) | DHFRHSP90AA1ADORA2AADORA1KMT2A | |
| SCHEMBL29515291 | 0.81 | DHFR (0.46) | LMNADHFRADORA2AADORA1EGFR | |
| SCHEMBL24331166 | 0.81 | DHFR (0.46) | LMNADHFRADORA2AADORA1EGFR | |
| SCHEMBL24331524 | 0.79 | GABRA1 (0.36) | DHFRHSP90AA1ADORA2AADORA1KMT2A | |
| SCHEMBL30588845 | 0.79 | MCHR1 (0.40) | DHFRHSP90AA1ADORA2AADORA1 | |
| SCHEMBL29515213 | 0.79 | GABRA1 (0.36) | DHFRHSP90AA1ADORA2AADORA1KMT2A | |
| SCHEMBL26126504 | 0.79 | MCHR1 (0.40) | DHFRHSP90AA1ADORA2AADORA1 | |
| SCHEMBL24330556 | 0.77 | NOS3 (0.35) | DHFRHSP90AA1ADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS (SAN DIEGO) LLC | 2023-11-23 | — | — | US | disclosed |
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2022076620-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230374038-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | LMNA 3964/4885DHFR 2100/4885HSP90AA1 1237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.